Develops and sells software for managing medical practices, including patient scheduling and electronic payments. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 24% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 78% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $588.0M a year; the problem isn’t sales — it’s costs running above that number.
There is $446.6M in the vault; even if every debt were paid off, $227.2M would remain.
Over the last 12 months, company executives reported 19 buys and 9 sells. Management buying with its own money is usually read as a good sign.
A loss of $86.5M against $588.0M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Sales are going backwards, not just slowing. Council score: 4/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.